Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment costs about $1,000 a month without insurance.

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment. The Wednesday ...

When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to secure CMS coverage for obesity drugs.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Eli Lilly (NYSE ... Mounjaro ($3.1 billion) and Zepbound ($1.3 billion). Late last year, regulators approved Zepbound as a ...